CPG No.

: PH /CPG/020 Issue date: 25 March 2020 Version: 1

Title: Levofloxacin Intravenous guideline ■New □Revised □Renewal

• Gram positive bacteria:
methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus
ACTIONS aureus (MRSA), Streptococcus pneumoniae, Listeria monocytogenes Effective date: 25 March 2020
Applicability: Medical Staff
• Gram negative bacteria:
Expiry date:N.
 Enterobacteriaceae, H. influenzae, other Haemophilus spp., N. gonorrhoeae, 24meningitides,
March 2022 M. catarrhalis, P.
aeruginosa, Stenotrophomonas maltophilia, S. maltophilia

• Atypicals:  Legionella pneumophilia

• Pneumonia: nosocomial and community acquired

INDICATIONS • Acute bacterial sinusitis
• Acute bacterial exacerbation of chronic bronchitis
• Skin and skin structure infections: complicated and uncomplicated
• Chronic bacterial prostatitis
• Urinary tract infections: complicated and uncomplicated
• Acute pyelonephritis

DOSAGE& Dosage in Adult Patients with Normal Renal Function

ADMINISTRATIO • The usual dose of Levofloxacin Injection is 250 mg OR
N • 500 mg administered by slow infusion over 60 minutes every 24 hours OR

• 750 mg administered by slow infusion over 90 minutes every 24 hours

IV Push
• IV Push not recommended

MONITORING • Blood pressure (rapid administration can cause hypotension)

Considerations for
IV Administration • Central or peripheral Maintain adequate hydration to prevent crystalluria

• Prolongation of QT interval; avoid concurrent use with other drugs that prolong QT interval and in patients with risk
PRECAUTIONS factors for torsades de pointes (hypokalemia, significant bradycardia, cardiomyopathy)

• Patients with glucose 6-phosphate dehydrogenase deficiency

• Diabetes mellitus; disturbances of blood glucose have been reported, usually in diabetic patients receiving concomitant
treatment with an oral hypoglycemic agent or with insulin

COMPATABILITY
• NS
• D5W

• Levofloxacin are associated with an increased risk of tendinitis and tendon rupture in all ages.
WARNING
• This risk is further increased in older patients usually over 60 years of age.

• In patients taking corticosteroid drugs, and in patients with kidney, heart.

• Janssen Ortho LLC, Gurabo, Puerto Rico ,Pharmaceutica N.V.

REFERENCES • PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Raritan, NJ
• http://www.fda.gov/downloads/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness

Levofloxacin Intravenous Guideline

1|Page